Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris.

Blood·1995
Same author

Determinants of plasma factor VIIa levels in humans.

Blood·1995
Same author

Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.

British journal of haematology·1995
Same author

Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.

American journal of hematology·1995
Same author

Hypercoagulability in centenarians: the paradox of successful aging.

Blood·1995

Related Experiment Video

Updated: Jul 13, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Thrombosis and bleeding disorders outside Western countries.

P M Mannucci1

  • 1Angelo Bianchi Bonomi Hemophilia, Thrombosis Center, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy. pmmannucci@libero.it

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed
Summary

Venous thromboembolism is not rare in Asia, necessitating thromboprophylaxis for high-risk patients. Hemophilia management has improved, with future strategies including recombinant factors and gene therapy.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: Jul 13, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Area of Science:

  • Hematology
  • Vascular Medicine
  • Biotechnology

Background:

  • Asia shows increasing awareness of bleeding and thrombotic disorders.
  • Venous thromboembolism was previously considered rare in Asia, but recent studies indicate otherwise.
  • Management of hemophilia and coagulation disorders has significantly improved across several Asian nations.

Purpose of the Study:

  • To highlight the evolving landscape of bleeding and thrombotic disorders in Asia.
  • To advocate for the implementation of thromboprophylaxis in high-risk medical and surgical cases.
  • To discuss advancements and future strategies in hemophilia management in Asia.

Main Methods:

  • Review of recent large-scale studies across multiple Asian countries.
  • Analysis of improvements in hemophilia care, including blood product availability and physician leadership.
  • Assessment of biotechnological capacities for future therapeutic developments.

Main Results:

  • Venous thromboembolism is more prevalent in Asia than previously assumed, challenging prior clinical practices.
  • Enhanced availability of blood products and expert leadership have improved hemophilia management.
  • Countries like China and India possess the biotechnological expertise for advanced therapies.

Conclusions:

  • The practice of withholding thromboprophylaxis in high-risk Asian patients should be discontinued.
  • Continued advancements in hemophilia care are evident, with promising future therapeutic avenues.
  • Biotechnology offers potential for advanced hemophilia treatment in populous Asian countries.